BioSpace News Archive

PharmaJet®, a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced the start of the first human clinical trial for a Venezuelan Equine Encephalitis (VEE) vaccine delivered with PharmaJet Precision Delivery Systems.

Gradalis, Inc. announced that it has been awarded a $9.9 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas.

Rosalind Franklin University of Medicine and Science announces the appointment of molecular biologist Weihang “Valerie” Chai, PhD, as director of the Center for Genetic Diseases.

Protagonist Therapeutics, Inc. reported that on November 15, 2023, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer letters.

AbCellera (Nasdaq: ABCL) today announced that management will present at the Piper Sandler 35th Annual Healthcare Conference in New York, New York on Thursday, November 30, 2023, at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time).

GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the highlights from its “ACLF Day” held on November 11, 2023 during AASLD The Liver Meeting ® in Boston, MA (USA).

Geron Corporation, a late-stage clinical biopharmaceutical company, reported that it has granted non-statutory stock options to purchase an aggregate of 438,950 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported third quarter 2023 financial results and provided a corporate update.

On November 16, the Canadian Medical Isotope Ecosystem (CMIE) - an initiative co-led by TRIUMF Innovations and the Centre for Probe Development and Commercialization

Cutera, Inc. announced that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on November 15, 2023 indicating that the Company is not currently in compliance with Nasdaq’s Listing Rules due to the Company’s inability to timely file its Form 10-Q for the period ended September 30, 2023 with the Securities and Exchange Commission.